 Subjects must meet all of the following criteria: 1 male or female 18-65 years of age; 2 type 2 diabetes based on the American Diabetes Association criteria; 3 HbA1c 6.5-9.0 while on diet alone or diet plus sulfonylurea or meglitinides therapy; 4 no history of thiazolidinediones, insulin, ACE inhibitor or AII-receptor blockade therapy; 5 taking no medications known to affect glycemic control or endothelial function, unless the medication has been stable for at least 3 months; 6 blood pressure equal or below 14090 mmHg; 7 not pregnant and willing to take appropriate contraceptive measures if capable of becoming pregnant; 8 serum creatinine below 1.7 mgdl in female and 1.8 mgdl in males; 9 ALT or AST less than 2 times the upper limit of normal for the laboratory and absence of clinical signs or symptoms of liver disease; 10 hematocrit 34 in females and 35 in males; 11 normal thyroid function; 12 no evidence of coronary heart disease by history or EKG or moderate to severe congestive heart failure NY Heart Association Cardiac Class III or IV; 13 no history or the presence of any clinically significant or unstable medical condition that makes the subject unlikely to complete the study in the opinion of the PI; and 14 absence of any condition or situations which would preclude adherence and completion of the protocol; 15 the ability to give voluntary informed consent. All clinical laboratory analyses for this trial will be performed at the central laboratory at the University of Texas Health Science Center in San Antonio. All research analytical determinations will be performed in the laboratories of the Diabetes Division. Eligible subjects will return one week after Visit 1 for a second visit Visit 2, a subject number will be assigned, and a nutritional assessment by a dietitian will be performed. A morning urine specimen will be collected for the determination of microalbumin-to-creatinine ratio. Patients also will have baseline determinations of circulating plasminogen activator inhibitor PAI-1, endothelin-1, VCAM, ECAM, p-selectin and e-selectin markers of endothelial damage, C-reactive protein and interleukins markers of inflammation; PAI-1 marker o hypercoagulable state; plasma lipids total HDLLDL cholesterol and triglycerides, as well as LDL and HDL particle size, and apolipoproteins A1, B and C-III. All personal data, anthropometric measurements height, weight, waist-to-hip ratio, dietary history, vital signs and clinical findings will be recorded in a confidential master file. 